Our Mission
The ACC Nevada Chapter is dedicated to advancing the field of cardiovascular care through innovation, advocacy, and professional development, ensuring that Nevada’s clinicians are equipped to meet the evolving health challenges of our state.
|
ACC Live Courses For a listing of all ACC Live Courses please visit: https://www.acc.org/education-and-meetings/meetings |
Please join your cardiology colleagues at the ACC Rockies Chapter Meeting in Park City, Utah for updates on ACC affairs, the potential new CV Board, and clinical topics such as Genetic and Sports EP, plus a discussion on the growing role of obesity medications in heart failure, and the first-ever Cardiology State-of-the-State report. There will be many opportunities for networking, as well!.
For more information and to register, please visit: 
Latest in Cardiology from ACC.org
- DANCAVAS 2 and ABC-AF Trials Explore Personalized Treatments For CV PreventionNew research exploring the potential of personalized treatments to detect and prevent cardiovascular disease was part of a prevention-focused hot line Session at ESC Congress 2025.
- HI-PRO: Apixaban Lowers Risk of VTE in Patients With Transient Provoking FactorsAt one year, low-intensity apixaban therapy results in lower risk of symptomatic recurrent venous thromboembolism (VTE) compared to placebo in patients with provoked VTE and enduring risk factors. Furthermore, it carries a low risk of major bleeding, according to efficacy and safety results of the HI-PRO trial, presented during ESC Congress 2025 and simultaneously published […]
- PREVENT-MINS: Ivabradine to Reduce Risk of Myocardial Injury After Noncardiac SurgeryIvabradine did not reduce the risk of myocardial injury after noncardiac surgery (MINS) compared with placebo in patients over the age of 45 years with, or at risk of, atherosclerotic disease, according to findings from the PREVENT-MINS trial presented at ESC Congress 2025.
- VICTORION-Difference: Inclisiran-Based Treatment Strategy For Patients With HypercholesterolemiaInclisiran on top of individually optimized lipid-lowering therapy helped more patients with hypercholesterolemia at high/very high risk of cardiovascular events achieve LDL cholesterol (LDL-C) goals compared with placebo, based on findings from the VICTORION-Difference trial presented at ESC Congress 2025.
- BaxHTN and KARDIA-3 Trials Explore Efficacy of HTN TreatmentsTwo hot line trials – BaxHTN and KARDIA-3 – presented at ESC Congress 2025 explore treatment options for patients with uncontrolled hypertension.